Stock 4599 STEMRIM
Add to a list
To use this feature you must be a member
Log inSign up

All News StemRIM

Equities

4599

JP3399690001

Market Closed - Japan Exchange
Other stock markets
 11:30:00 24/05/2024 am IST 		5-day change 1st Jan Change
457 JPY +1.11% Intraday chart for StemRIM 0.00% -20.93%
09/05 StemRIM to Seek Shareholders' Approval on Capital Stock Reduction MT
13/03 StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
StemRIM to Seek Shareholders' Approval on Capital Stock Reduction
MT
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy
CI
StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders
CI
StemRIM Allocates 300 Stock Options to R&D Partner
MT
StemRIM to Issue Stock Acquisition Rights
MT
StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation
MT
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co
CI
StemRIM Issues 433,000 Shares as Restricted Stock Compensation
MT
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration
MT
StemRIM Discloses Issuance Details of Stock Options to Directors
MT
Stemrim Inc. Announces Patent Registration (Us) for the Use of the Hmgb1 Fragment Peptide, Redasemtide
CI
StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction
CI
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke
CI
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China
CI
StemRIM Inc. Announces Patent Registration for the Use of the Hmgb1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
CI
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023
CI
Shionogi & Co., Ltd. - Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa
AQ
StemRIM Inc. Announces Publication of Scientific Articles for Stem Cell Gene Therapy
CI
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
CI
StemRIM Bags 450 Million Yen Milestone Payment From Shionogi; Details FY23 Earnings Outlook, Liver Disease Trial Results
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4599 Stock
  4. News StemRIM